This study designed to elucidate dynamics of lipid metabolism and HbA(1c) level, uricemia, and renal function in 54 patients with chronic renal disease (CRD) of non-diabetic genesis treated by standard cardioprotective therapy in combination with atorvastatin. The patients were divided in two groups with glomerular filtration rate (GFR) < 60 ml/min (n = 31) and = > 60 ml/min. The former were given 20 mg atorvastatin/day. Arterial pressure (AP): systolic (SAP), diastolic (DAP), and pulse (PAP) pressure, plasma lipid profile, uricemia, HbA(1c) and GFR were measured at admission and 6 months after the onset of therapy. The use of atorvastatin in combined therapy of CRD of non-diabetic genesis resulted in a significant decrease of the levels of atherogenic lipids, HbA(1c), uricemia, lipid peroxidation, SAP and PAP (by 4-5 mm Hg) while the initially low GFR (< 60 ml/min) increased. It is concluded that therapy of chronic renal disease of non-diabetic genesis with atorvastatin not only improves lipid metabolism but also decreases HbA(1c) level and uricemia, normalizes AP and renal function.
Download full-text PDF |
Source |
---|
BMC Nephrol
January 2025
Department of Renal Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 35, Aarhus N, 8200, Denmark.
Background: Patients treated with chronic dialysis or kidney transplantation have difficulties in maintaining employment. We aimed to estimate employment rates among dialysis and kidney transplant patients from 3 years before to 3 years after initiating dialysis or undergoing transplantation.
Methods: All first-time dialysis and kidney transplantation patients aged 18-65 years in Denmark from 2005 to 2019 were identified using the Danish Nephrological Register and linked with information about social security benefits.
BMC Nephrol
January 2025
Department of Nephrology-Dialysis-Transplantation, University of Liège, CHU Sart Tilman, Liège, Belgium.
Background: Creatinine-based estimated glomerular filtration rate (eGFR) equations are widely used in clinical practice but exhibit inherent limitations. On the other side, measuring GFR is time consuming and not available in routine clinical practice. We developed and validated machine learning models to assess the trustworthiness (i.
View Article and Find Full Text PDFSci Rep
January 2025
First Department of Medicine, Medical School, University of Pécs, Ifjúság Útja 13, 7624, Pécs, Hungary.
Both acute kidney injury and chronic kidney disease are risk factors for many outcomes of gastrointestinal bleeding (GIB). These are associated with higher mortality, longer hospitalisation, and greater need for transfusion in case of overt GIB. Our study aimed to further evaluate the role of kidney function in several clinical outcomes of GIB patients.
View Article and Find Full Text PDFNat Rev Dis Primers
January 2025
Division of Nephrology, Department of Medicine IV, Hospital of the Ludwig-Maximilians University, Munich, Germany.
Chronic kidney disease (CKD) is defined by persistent abnormalities of kidney function or structure that have consequences for the health. A progressive decline of excretory kidney function has effects on body homeostasis. CKD is tightly associated with accelerated cardiovascular disease and severe infections, and with premature death.
View Article and Find Full Text PDFNefrologia (Engl Ed)
January 2025
Division of Nephrology IIS-Fundacion Jimenez Diaz, Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; RICORS2040, Carlos III Institute of Health, Madrid, Spain.
Introduction: Chronic kidney disease (CKD) is associated with high cardiovascular disease (CVD) risk, and requires specific interventions to decreases CVD risk. The guidelines indicate that systematic global CVD risk assessment is recommended in individuals with any major vascular risk factor. The European Society Cardiology (ESC) guidelines, he European Renal Association (ERA) Council and the Spanish Society of Nephrology (S.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!